Abstract
The objective of this study is to measure the chronic responses of 9L glioma and normal brain to photodynamic therapy (PDT). Tumor size, proliferation activity of glioma cells, and vascular endothelial growth factor (VEGF) expression in both the tumor area and the brain adjacent to tumor (BAT) were observed 7 days after clinically relevant doses of PDT treatment. 9L Gliosarcoma cells were implanted into the brain of 20 athymic nude mice. Fifteen mice were injected intraperitoneally with Photofrin™ at a dose of 2 mg/kg on day 6 after tumor implantation and were treated with laser at different optical doses of 40 J/cm2 (n = 5), 80 J/cm2 (n = 5), and 120 J/cm2 (n = 5) at 24 h after Photofrin injection, respectively. The remaining five tumor-bearing mice served as a tumor-only control. All animals were killed 14 days after tumor implantation. Hematoxylin and eosin and immunostaining were performed to assess tumor volume, VEGF expression in the tumor and the BAT, as well as Ki67 expression in the tumor area. The tumor volume of the mice receiving 80 or 120 J/cm2 group was significantly smaller than the control group (p < 0.01). VEGF immunoreactivity in the BAT was significantly increased in the 120 J/cm2 PDT-treated mice (p < 0.001), compared with the immunoreactivity seen in untreated mice and those receiving Photofrin and lower optical doses. No significant differences were detected in the proliferation of glioma cells and VEGF expression in the tumor area between these groups. These data indicate that PDT can shrink tumor, especially at the high light dose, and that PDT induces expression of VEGF in the BAT, which is associated with tumor recurrence. Therefore, PDT combined with anti-angiogenic agents may be an effective treatment strategy for glioma.
Similar content being viewed by others
References
Wilson BC (2002) Photodynamic therapy for cancer: principles. Can J Gastroenterol 16:393–396
Kostron H, Plangger C, Fritsch E, Maier H (1990) Photodynamic treatment of malignant brain tumors. Wien Klin Wochenschr 102:531–535
Muller P, Wilson B (1991) Photodynamic therapy of brain tumours—post-operative “field fractionation”. J Photochem Photobiol B 9:117–119
Jiang F, Lilge L, Logie B, Li Y, Chopp M (1997) Photodynamic therapy of 9L gliosarcoma with liposome-delivered Photofrin. Photochem Photobiol 65:701–706
Jiang F, Lilge L, Grenier J, Li Y, Wilson MD, Chopp M (1998) Photodynamic therapy of U87 human glioma in nude rat using liposome-delivered Photofrin. Lasers Surg Med 22:74–80
Jiang F, Lilge L, Belcuig M, Singh G, Grenier J, Li Y, Chopp M (1998) Photodynamic therapy using Photofrin in combination with buthionine sulfoximine (BSO) to treat 9L gliosarcoma in rat brain. Lasers Surg Med 23:161–166
Chopp M, Madigan L, Dereski M, Jiang F, Li Y (1996) Photodynamic therapy of human glioma (U87) in the nude rat. Photochem Photobiol 64:707–711
George JE 3rd, Ahmad Y, Varghai D, Li X, Berlin J, Jackowe D, Jungermann M, Wolfe MS, Lilge L, Totonchi A, Morris RL, Peterson A, Lust WD, Kenney ME, Hoppel CL, Sun J, Oleinick NL, Dean D (2005) Pc 4 photodynamic therapy of U87-derived human glioma in the nude rat. Lasers Surg Med 36:383–389
Lilge L, Portnoy M, Wilson BC (2000) Apoptosis induced in vivo by photodynamic therapy in normal brain and intracranial tumour tissue. Br J Cancer 83:1110–1117
Stylli SS, Kaye AH, MacGregor L, Howes M, Rajendra P (2005) Photodynamic therapy of high grade glioma—long term survival. J Clin Neurosci 12:389–398
Muller PJ, Wilson BC (1996) Photodynamic therapy for malignant newly diagnosed supratentorial gliomas. J Clin Laser Med Surg 14:263–270
Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710–1715
Shiba M, Kohno H, Kakizawa K, Iizasa T, Otsuji M, Saitoh Y, Hiroshima K, Ohwada H, Fujisawa T (2000) Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected nonsmall cell lung carcinoma. Cancer 89:1457–1465
Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ (2000) Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 60:4066–4069
Plate KH, Breier G, Weich HA, Mennel HD, Risau W (1994) Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59:520–529
Jiang F, Zhang ZG, Katakowski M, Robin AM, Faber M, Zhang F, Chopp M (2004) Angiogenesis induced by photodynamic therapy in normal rat brains. Photochem Photobiol 79:494–498
Zhang X, Jiang F, Zhang ZG, Kalkanis SN, Hong X, Decarvalho AC, Chen J, Yang H, Robin AM, Chopp M (2005) Low-dose photodynamic therapy increases endothelial cell proliferation and VEGF expression in nude mice brain. Lasers Med Sci 20:74–79
Hong X, Jiang F, Kalkanis SN, Zhang ZG, Zhang XP, DeCarvalho AC, Katakowski M, Bobbitt K, Mikkelsen T, Chopp M (2006) SDF-1 and CXCR4 are up-regulated by VEGF and contribute to glioma cell invasion. Cancer Lett 236:39–45
Zhou Q, Olivo M, Lye KY, Moore S, Sharma A, Chowbay B (2005) Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. Cancer Chemother Pharmacol 56:569–577
Dimitroff CJ, Klohs W, Sharma A, Pera P, Driscoll D, Veith J, Steinkampf R, Schroeder M, Klutchko S, Sumlin A, Henderson B, Dougherty TJ, Bernacki RJ (1999) Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs 17:121–135
Acknowledgements
The authors thank Cynthia Roberts, Qing-e Lu and Yuping Yang for technical assistance. This work was supported by NIH grants PO1 CA043892 and RO1 CA100486.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, X., Jiang, F., Kalkanis, S.N. et al. Post-acute response of 9L gliosarcoma to Photofrin™-mediated PDT in athymic nude mice. Lasers Med Sci 22, 253–259 (2007). https://doi.org/10.1007/s10103-007-0442-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10103-007-0442-1